LYVE1 and neoplasm: Latil et al. (2003) reported that LYVE1 was downregulated in prostate cancer and was related to the relapse. In hepatocellular carcinoma and ovarian cancer, its expression was also decreased and played the tumor-suppressive effect (Llovet et al., 2006; Gao et al., 2017).